BMY•benzinga•
UBS Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $54
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 11, 2025 by benzinga